


Supplementary figure 4



Supplementary figure 4

(A) Analysis of the ASC-SLE gene signature for the top 3 enriched pathways. Threshold defines the significance level of $p=0.05$. (B) Overall IFN gene signature score for each individual from the non-interventional exploratory study;.

(C) Correlation plot between plasma IFN- α and the IFN gene signature score from whole blood from all individuals of the non-interventional exploratory study. Blue, healthy subjects, black, patients with SLE, r = Spearman value, p = p -value, 2-tailed t test. (D) Correlation plot between ASC number and the WB-SLE gene signature score from all individuals of the non-interventional exploratory study. Blue, healthy subjects, black, patients with SLE, r = Spearman value, (2-tailed t test). (E) Plasma pan-IFN- α protein as a percentage of baseline after 12 weeks of cenerimod treatment versus placebo from the phase 2 SLE study. Dotted lines represent the no change level in biomarker concentration compared to baseline (100%). Results are displayed as mean plus standard error of the mean. p -values (Mann-Whitney test) are given where statistically significant. (F) Absolute plasma levels of Galectin-9, CXCL9 and CXCL10 after 12 weeks of cenerimod treatment versus placebo from the phase 2 SLE study.